These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 7585512

  • 1. Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function.
    Ewing CM, Ru N, Morton RA, Robinson JC, Wheelock MJ, Johnson KR, Barrett JC, Isaacs WB.
    Cancer Res; 1995 Nov 01; 55(21):4813-7. PubMed ID: 7585512
    [Abstract] [Full Text] [Related]

  • 2. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells.
    Morton RA, Ewing CM, Nagafuchi A, Tsukita S, Isaacs WB.
    Cancer Res; 1993 Aug 01; 53(15):3585-90. PubMed ID: 8339265
    [Abstract] [Full Text] [Related]

  • 3. Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin.
    Tomita K, van Bokhoven A, Jansen CF, Bussemakers MJ, Schalken JA.
    Biochem Biophys Res Commun; 2000 Jan 27; 267(3):870-4. PubMed ID: 10673383
    [Abstract] [Full Text] [Related]

  • 4. A truncated beta-catenin disrupts the interaction between E-cadherin and alpha-catenin: a cause of loss of intercellular adhesiveness in human cancer cell lines.
    Oyama T, Kanai Y, Ochiai A, Akimoto S, Oda T, Yanagihara K, Nagafuchi A, Tsukita S, Shibamoto S, Ito F.
    Cancer Res; 1994 Dec 01; 54(23):6282-7. PubMed ID: 7954478
    [Abstract] [Full Text] [Related]

  • 5. Cadherin dysfunction in a human cancer cell line: possible involvement of loss of alpha-catenin expression in reduced cell-cell adhesiveness.
    Shimoyama Y, Nagafuchi A, Fujita S, Gotoh M, Takeichi M, Tsukita S, Hirohashi S.
    Cancer Res; 1992 Oct 15; 52(20):5770-4. PubMed ID: 1394201
    [Abstract] [Full Text] [Related]

  • 6. Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection.
    Luo J, Lubaroff DM, Hendrix MJ.
    Cancer Res; 1999 Aug 01; 59(15):3552-6. PubMed ID: 10446959
    [Abstract] [Full Text] [Related]

  • 7. Alterations of the cadherin-catenin cell adhesion system in cancers.
    Kanai Y, Oda T, Shimoyama Y, Ochiai A, Oyama T, Yoshiura K, Akimoto S, Yamada T, Hirohashi S.
    Princess Takamatsu Symp; 1994 Aug 01; 24():51-62. PubMed ID: 8983063
    [Abstract] [Full Text] [Related]

  • 8. Frequent alterations in E-cadherin and alpha- and beta-catenin expression in human breast cancer cell lines.
    Pierceall WE, Woodard AS, Morrow JS, Rimm D, Fearon ER.
    Oncogene; 1995 Oct 05; 11(7):1319-26. PubMed ID: 7478552
    [Abstract] [Full Text] [Related]

  • 9. Wnt-1 and int-2 mammary oncogene effects on the beta-catenin pathway in immortalized mouse mammary epithelial cells are not sufficient for tumorigenesis.
    Hollmann CA, Kittrell FS, Medina D, Butel JS.
    Oncogene; 2001 Nov 15; 20(52):7645-57. PubMed ID: 11753642
    [Abstract] [Full Text] [Related]

  • 10. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival.
    Richmond PJ, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M.
    Cancer Res; 1997 Aug 01; 57(15):3189-93. PubMed ID: 9242448
    [Abstract] [Full Text] [Related]

  • 11. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer.
    Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, Debruyne FM, Isaacs WB.
    Cancer Res; 1992 Sep 15; 52(18):5104-9. PubMed ID: 1516067
    [Abstract] [Full Text] [Related]

  • 12. Pancreatic carcinoma: correlation between E-cadherin and alpha-catenin expression status and liver metastasis.
    Gunji N, Oda T, Todoroki T, Kanazawa N, Kawamoto T, Yuzawa K, Scarpa A, Fukao K.
    Cancer; 1998 May 01; 82(9):1649-56. PubMed ID: 9576284
    [Abstract] [Full Text] [Related]

  • 13. Changes in growth and tumorigenicity following reconstitution of retinoblastoma gene function in various human cancer cell types by microcell transfer of chromosome 13.
    Banerjee A, Xu HJ, Hu SX, Araujo D, Takahashi R, Stanbridge EJ, Benedict WF.
    Cancer Res; 1992 Nov 15; 52(22):6297-304. PubMed ID: 1423276
    [Abstract] [Full Text] [Related]

  • 14. Cadherin switching in human prostate cancer progression.
    Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ, Schalken JA.
    Cancer Res; 2000 Jul 01; 60(13):3650-4. PubMed ID: 10910081
    [Abstract] [Full Text] [Related]

  • 15. Molecular aspects of adhesion-epigenetic mechanisms for inactivation of the E-Cadherin-mediated cell adhesion system in cancers.
    Hirohashi S.
    Verh Dtsch Ges Pathol; 2000 Jul 01; 84():28-32. PubMed ID: 11217445
    [Abstract] [Full Text] [Related]

  • 16. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness.
    Zi X, Guo Y, Simoneau AR, Hope C, Xie J, Holcombe RF, Hoang BH.
    Cancer Res; 2005 Nov 01; 65(21):9762-70. PubMed ID: 16266997
    [Abstract] [Full Text] [Related]

  • 17. E-cadherin-catenin cell-cell adhesion complex and human cancer.
    Wijnhoven BP, Dinjens WN, Pignatelli M.
    Br J Surg; 2000 Aug 01; 87(8):992-1005. PubMed ID: 10931041
    [Abstract] [Full Text] [Related]

  • 18. Plakoglobin induces desmosome formation and epidermoid phenotype in N-cadherin-expressing squamous carcinoma cells deficient in plakoglobin and E-cadherin.
    Parker HR, Li Z, Sheinin H, Lauzon G, Pasdar M.
    Cell Motil Cytoskeleton; 1998 Aug 01; 40(1):87-100. PubMed ID: 9605974
    [Abstract] [Full Text] [Related]

  • 19. Alterations in beta-catenin phosphorylation and plakoglobin expression in human breast cancer cells.
    Sommers CL, Gelmann EP, Kemler R, Cowin P, Byers SW.
    Cancer Res; 1994 Jul 01; 54(13):3544-52. PubMed ID: 8012979
    [Abstract] [Full Text] [Related]

  • 20. Cell-cell adhesion molecules and signaling intermediates and their role in the invasive potential of prostate cancer cells.
    Davies G, Jiang WG, Mason MD.
    J Urol; 2000 Mar 01; 163(3):985-92. PubMed ID: 10688036
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.